Recent insights into the role of ChREBP in intestinal fructose absorption and metabolism

被引:47
作者
Lee, Ho-Jae [1 ]
Cha, Ji-Young [1 ,2 ]
机构
[1] Gachon Univ, Coll Med, Lee Gil Ya Canc & Diabet Inst, Dept Biochem, Incheon 21999, South Korea
[2] Gil Med Ctr, Gachon Med Inst, Incheon 21565, South Korea
基金
新加坡国家研究基金会;
关键词
ChREBP; Fructose intolerance; Fructose metabolism; Irritable bowel syndrome; Small intestine; ELEMENT-BINDING PROTEIN; GENE-EXPRESSION; TRANSCRIPTION FACTOR; XYLULOSE; 5-PHOSPHATE; NUCLEAR-LOCALIZATION; INSULIN-RESISTANCE; SYNERGISTIC ACTION; MESSENGER-RNA; GLUCOSE; GLUT5;
D O I
10.5483/BMBRep.2018.51.9.197
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fructose in the form of sucrose and high fructose corn syrup is absorbed by the intestinal transporter and mainly metabolized in the small intestine. However, excess intake of fructose overwhelms the absorptive capacity of the small intestine, leading to fructose malabsorption. Carbohydrate response element-binding protein (ChREBP) is a basic helix-loop-helix leucine zipper transcription factor that plays a key role in glycolytic and lipogenic gene expression in response to carbohydrate consumption. While ChREBP was initially identified as a glucose-responsive factor in the liver, recent evidence suggests that ChREBP is essential for fructose-induced lipogenesis and gluconeogenesis in the small intestine as well as in the liver. We recently identified that the loss of ChREBP leads to fructose intolerance via insufficient induction of genes involved in fructose transport and metabolism in the intestine. As fructose consumption is increasing and closely associated with metabolic and gastrointestinal diseases, a comprehensive understanding of cellular fructose sensing and metabolism via ChREBP may uncover new therapeutic opportunities. In this mini review, we briefly summarize recent progress in intestinal fructose metabolism, regulation and function of ChREBP by fructose, and delineate the potential mechanisms by which excessive fructose consumption may lead to irritable bowel syndrome.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 76 条
[1]  
ANDERSSON DEH, 1978, ACTA MED SCAND, V203, P87
[2]   Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes [J].
Arden, Catherine ;
Tudhope, Susan J. ;
Petrie, John L. ;
Al-Oanzi, Ziad H. ;
Cullen, Kirsty S. ;
Lange, Alex J. ;
Towle, Howard C. ;
Agius, Loranne .
BIOCHEMICAL JOURNAL, 2012, 443 :111-123
[3]   Hepatic Elovl6 gene expression is regulated by the synergistic action of ChREBP and SREBP-1c [J].
Bae, Jin-Sik ;
Oh, Ah-Reum ;
Lee, Ho-Jae ;
Ahn, Yong-ho ;
Cha, Ji-Young .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (03) :1060-1066
[4]   Slc2a5 (Glut5) Is Essential for the Absorption of Fructose in the Intestine and Generation of Fructose-induced Hypertension [J].
Barone, Sharon ;
Fussell, Stacey L. ;
Singh, Anurag Kumar ;
Lucas, Fred ;
Xu, Jie ;
Kim, Charles ;
Wu, Xudong ;
Yu, Yiling ;
Amlal, Hassane ;
Seidler, Ursula ;
Zuo, Jian ;
Soleimani, Manoocher .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (08) :5056-5066
[5]   THE GLUT5 HEXOSE TRANSPORTER IS ALSO LOCALIZED TO THE BASOLATERAL MEMBRANE OF THE HUMAN JEJUNUM [J].
BLAKEMORE, SJ ;
ALEDO, JC ;
JAMES, J ;
CAMPBELL, FC ;
LUCOCQ, JM ;
HUNDAL, HS .
BIOCHEMICAL JOURNAL, 1995, 309 :7-12
[6]   ChREBP Mediates Glucose Repression of Peroxisome Proliferator-activated Receptor α Expression in Pancreatic β-Cells [J].
Boergesen, Michael ;
Poulsen, Lars la Cour ;
Schmidt, Soren Fisker ;
Frigerio, Francesca ;
Maechler, Pierre ;
Mandrup, Susanne .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (15) :13214-13225
[7]  
Bray GA, 2004, AM J CLIN NUTR, V79, P537
[8]   Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice [J].
Bricambert, Julien ;
Miranda, Jonatan ;
Benhamed, Fadila ;
Postic, Jean Girard Catherine ;
Dentin, Renaud .
JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (12) :4316-4331
[9]  
BURANT CF, 1992, J BIOL CHEM, V267, P14523
[10]   Management of the irritable bowel syndrome [J].
Camilleri, M .
GASTROENTEROLOGY, 2001, 120 (03) :652-668